使用奥氮平或氟哌啶醇治疗的首发精神病患者体重增加的病程及预测因素
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
作者信息
Zipursky Robert B, Gu Hongbin, Green Alan I, Perkins Diana O, Tohen Mauricio F, McEvoy Joseph P, Strakowski Stephen M, Sharma Tonmoy, Kahn René S, Gur Raquel E, Tollefson Gary D, Lieberman Jeffrey A
机构信息
Schizophrenia Programme,Centre for Addiction and Mental Health, 250 College Street, Toronto, Ontario, Canada M5T 1R8.
出版信息
Br J Psychiatry. 2005 Dec;187:537-43. doi: 10.1192/bjp.187.6.537.
BACKGROUND
Substantial weight gain is common with many atypical antipsychotics.
AIMS
To evaluate the extent, time course and predictors of weight gain and its effect on study retention among people with first-episode psychosis treated with olanzapine or haloperidol.
METHOD
Survival analysis assessed time to potentially clinically significant weight gain (> or =7%) and the effect of weight gain on study retention. Weight gain during the 2-year study was summarised using last-observation-carried-forward (LOCF), observed cases and study completion approaches.
RESULTS
After 2 years of treatment, LOCF mean weight gain was 10.2 kg (s.d.=10.1) for olanzapine (n=131) and 4.0 kg (s.d.=7.3) for haloperidol (n=132); observed cases mean weight gain was 15.4 kg (s.d.=10.0) for olanzapine and 7.5 kg (s.d.=9.2) for haloperidol. Change in body mass index was significantly predicted only by treatment group (P < 0.0001).
CONCLUSIONS
Olanzapine was associated with significantly greater weight gain than haloperidol, with both leading to greater weight gain than previously described.
背景
许多非典型抗精神病药物都会导致显著体重增加。
目的
评估使用奥氮平或氟哌啶醇治疗的首发精神病患者体重增加的程度、时间进程和预测因素，及其对研究保留率的影响。
方法
生存分析评估达到潜在临床显著体重增加（≥7%）的时间以及体重增加对研究保留率的影响。使用末次观察结转（LOCF）、观察病例和研究完成方法总结了2年研究期间的体重增加情况。
结果
治疗2年后，奥氮平组（n = 131）采用LOCF法的平均体重增加为10.2 kg（标准差 = 10.1），氟哌啶醇组（n = 132）为4.0 kg（标准差 = 7.3）；奥氮平组观察病例的平均体重增加为15.4 kg（标准差 = 10.0），氟哌啶醇组为7.5 kg（标准差 = 9.2）。体重指数的变化仅由治疗组显著预测（P < 0.0001）。
结论
与氟哌啶醇相比，奥氮平导致的体重增加显著更多，且两者导致的体重增加均高于先前描述的情况。
Zotero 插件